CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and
feasibility of chimeric antigen receptor 19 (CD19 CART) cells in relapsed and refractory
patients with CD19+ B cell lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shenzhen Second People's Hospital
Collaborator:
The Beijing Pregene Science and Technology Company, Ltd.